TNSN03127A1 - Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique - Google Patents

Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique

Info

Publication number
TNSN03127A1
TNSN03127A1 TNPCT/US2002/017067A TNSN03127A TNSN03127A1 TN SN03127 A1 TNSN03127 A1 TN SN03127A1 TN SN03127 A TNSN03127 A TN SN03127A TN SN03127 A1 TNSN03127 A1 TN SN03127A1
Authority
TN
Tunisia
Prior art keywords
composition
acutically
inhibitor
subject
cox
Prior art date
Application number
TNPCT/US2002/017067A
Other languages
English (en)
Inventor
Guang Wei Lu
Gary D Ewing
Praveen Tyle
Brenda M Stoller
Rajeev Gokhale
Ashwini Gadre
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN03127A1 publication Critical patent/TNSN03127A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNE COMPOSITION PHARMACEUTIQUE, POUVANT ETRE DELIVREE PAR VOIE DERMIQUE, COMPREND AU MOINS UN MEDICAMENT INHIBITEUR DE CYCLO-OXYGENASE-2 (COX-2) SELECTIF OU UN DE SES PRECURSEURS MEDICAMENTEUX, SOLUBILISE DANS UN VEHICULE PHARMACEUTIQUEMENT ACCEPTABLE QUI COMPREND UN ALCOOL MONOHYDROXYLIQUE DE BAS POIDS MOLECULAIRE, ET PRESENTE UNE VITESSE DE PENETRATION CUTANEE DE L'AGENT THERAPEUTIQUE AU MOINS EGALE A CELLE PRESENTEE PAR UNE SOLUTION DE REFERENCE DE L'AGENT THERAPEUTIQUE DANS UNE SOLUTION AQUEUSE D'ETHANOL A 70%.UNE METHODE POUR EFFECTUER L'ADMINISTRATION CIBLEE D'UN MEDICAMENT INHIBITEUR DE COX-2 SELECTIF A UN SITE DE DOULEUR ET/OU D'INFLAMMATION CHEZ UN SUJET COMPREND L'ADMINISTRATION TOPIQUE D'UNE TELLE COMPOSITION A LA PEAU DU SUJET, DE PREFERENCE A UN ENDROIT RECOUVRANT LE, OU ADJACENT AU, SITE DE DOULEUR ET/OU D'INFLAMMATION. UNE METHODE POUR EFFECTUER LE TRAITEMENT SYSTEMATIQUE D'UN SUJET SOUFFRANT D'UNE AFFECTION A MEDIATION PAR LA COX-2 COMPREND L'ADMINISTRATION TRANSDERMIQUE D'UNE TELLE COMPOSITION, DE PREFERENCE PAR MISE EN CONTACT DE LA COMPOSITION AVEC UNE SURFACE CUTANEE DU SUJET NON SUPERIEURE A ENVIRON 400 CM2.
TNPCT/US2002/017067A 2001-05-31 2002-05-30 Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique TNSN03127A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29483801P 2001-05-31 2001-05-31
US35075601P 2001-11-13 2001-11-13

Publications (1)

Publication Number Publication Date
TNSN03127A1 true TNSN03127A1 (fr) 2005-12-23

Family

ID=26968778

Family Applications (1)

Application Number Title Priority Date Filing Date
TNPCT/US2002/017067A TNSN03127A1 (fr) 2001-05-31 2002-05-30 Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique

Country Status (25)

Country Link
US (1) US20030161867A1 (fr)
EP (1) EP1404345A2 (fr)
JP (1) JP2004532871A (fr)
KR (1) KR20040033286A (fr)
CN (1) CN1547474A (fr)
AP (1) AP2003002922A0 (fr)
BR (1) BR0210104A (fr)
CA (1) CA2448627A1 (fr)
CO (1) CO5640125A2 (fr)
CR (1) CR7173A (fr)
CZ (1) CZ20033241A3 (fr)
EA (1) EA200301200A1 (fr)
EC (1) ECSP034869A (fr)
HU (1) HUP0600294A2 (fr)
IL (1) IL159100A0 (fr)
IS (1) IS7055A (fr)
MA (1) MA27030A1 (fr)
MX (1) MXPA03010991A (fr)
NO (1) NO20035325D0 (fr)
OA (1) OA12613A (fr)
PL (1) PL367337A1 (fr)
SK (1) SK14762003A3 (fr)
TN (1) TNSN03127A1 (fr)
WO (1) WO2002096435A2 (fr)
ZA (1) ZA200309298B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4283507B2 (ja) * 2002-08-02 2009-06-24 久光製薬株式会社 経皮投与用貼付剤
US20040127531A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
US20040126415A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
US20050020658A1 (en) * 2002-11-21 2005-01-27 Katsuyuki Inoo Selective cyclooxygenase-2 inhibitor patch
EP1589973B2 (fr) * 2003-01-23 2012-12-26 Shire Biopharmaceuticals Holdings Ireland Limited Formulation et methodes de traitement de la thrombocythemie
CA2541265A1 (fr) * 2003-10-08 2005-04-28 Novartis Ag Compositions pharmaceutiques contenant un acide 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetique
WO2005044227A1 (fr) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Compositions pharmaceutiques topiques
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
JP2008526963A (ja) * 2005-01-14 2008-07-24 リポ ケミカルズ インコーポレイテッド 過度に色素沈着した皮膚を処置するための組成物および方法
US20060251689A1 (en) * 2005-03-30 2006-11-09 Astion Development A/S Treatment or prevention of pruritus
EP1890687B1 (fr) * 2005-06-14 2008-09-17 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Gel pharmaceutique stable de diclofénac sodique
US20120040809A1 (en) 2010-08-11 2012-02-16 Formicola Thomas M Stretch-Out Roll Up Bar
US20070243275A1 (en) * 2006-04-13 2007-10-18 Gilbard Jeffrey P Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
NZ577020A (en) 2006-10-17 2012-05-25 Nuvo Res Inc Diclofenac gel containing dimethyl sulfoxide (dmso)
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
DE102007034976A1 (de) 2007-07-26 2009-01-29 Bayer Healthcare Ag Arzneimittel zur transdermalen Anwendung bei Tieren
WO2010008600A1 (fr) * 2008-07-16 2010-01-21 Dermworx Incorporated Système d'apport de médicament topique
WO2010046238A1 (fr) 2008-10-20 2010-04-29 Unilever Nv Composition antimicrobienne
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
CA2760591C (fr) 2009-05-01 2018-01-02 Advanced Vision Research, Inc. Compositions de nettoyant et procedes d'utilisation de celles-ci
WO2011036048A1 (fr) 2009-09-24 2011-03-31 Unilever Nv Agent désinfectant comprenant de l'eugénol, du terpinéol et du thymol
WO2011041609A2 (fr) * 2009-09-30 2011-04-07 Nuvo Research Inc. Formulations topiques
EP2485730A1 (fr) 2009-10-09 2012-08-15 Nuvo Research Inc. Formulation topique comprenant de l'étoricoxib et tensio-actif zwitterionique
EP2575813A1 (fr) * 2010-05-28 2013-04-10 Nuvo Research Inc. Formulation topique d'étoricoxib
EA201201632A1 (ru) * 2010-05-31 2013-04-30 Юнилевер Н.В. Композиция для ухода за кожей
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
CN103354741B (zh) 2010-12-07 2016-01-13 荷兰联合利华有限公司 口腔护理组合物
ES2626134T3 (es) 2011-01-04 2017-07-24 Bausch & Lomb Incorporated Composiciones de bepotastina
EP2691077B1 (fr) * 2011-03-31 2018-05-09 Integumen Ireland Limited Preparation topique contenant de l'acide salicylique
US20130089575A1 (en) * 2011-10-05 2013-04-11 Douglas Pharmaceuticals Ltd. Pharmaceutical methods and topical compositions containing acitretin
IN2014MN00808A (fr) 2011-11-03 2015-09-04 Unilever Plc
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) * 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
EP2979695B1 (fr) * 2013-03-29 2018-08-01 AskAt Inc. Agent thérapeutique pour trouble oculaire
KR101934169B1 (ko) * 2013-12-24 2018-12-31 더 프록터 앤드 갬블 캄파니 피부 케어 활성제의 증진된 침투를 제공하는 화장 조성물 및 방법
US20180271813A1 (en) * 2014-11-10 2018-09-27 Achelios Therapeutics, Inc. Sprayable analgesic compositions
PL3316856T3 (pl) 2015-06-30 2021-10-25 Sequessome Technology Holdings Limited Zmieszane formulacje
CN105663032A (zh) * 2016-02-23 2016-06-15 青岛科技大学 一种维他昔布软膏剂的制备方法
CN106267218A (zh) * 2016-10-18 2017-01-04 华北理工大学 4‑萜品醇脂肪酸酯衍生物及其应用和制备方法
KR102042456B1 (ko) * 2018-03-22 2019-11-08 크리스탈지노믹스(주) 경피흡수제제
CN112203643A (zh) * 2018-05-31 2021-01-08 国立大学法人九州大学 经皮吸收制剂
RU2685436C1 (ru) * 2018-06-22 2019-04-18 ЗАО "ФармФирма "Сотекс" Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
KR20220001170A (ko) 2020-06-29 2022-01-05 김종림 앙카볼트
KR102619716B1 (ko) * 2020-10-20 2023-12-29 고려대학교 산학협력단 저온에서도 우수한 항균활성을 갖는 항진균용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3526887B2 (ja) * 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996037476A1 (fr) * 1995-05-25 1996-11-28 G.D. Searle & Co. Procede de preparation de 3-haloalkyl-1h-pyrazoles
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
TR199802049T2 (xx) * 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP0863134A1 (fr) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
GB2340751B (en) * 1998-08-12 2003-11-05 Edko Trading Representation Pharmaceutical compositions
WO2000025779A1 (fr) * 1998-11-02 2000-05-11 Merck & Co., Inc. Methode de traitement des migraines et compositions pharmaceutiques associees
AU3470600A (en) * 1999-01-14 2000-08-01 David Houze Compositions and methods for drug delivery
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2000072883A2 (fr) * 1999-06-02 2000-12-07 Aviana Biopharm Compositions pharmaceutiques transdermiques
IN191512B (fr) * 2000-01-21 2003-12-06 Panacea Biotech
JP2004503588A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−２阻害薬および血管調節化合物
IN191090B (fr) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Also Published As

Publication number Publication date
US20030161867A1 (en) 2003-08-28
IS7055A (is) 2003-11-27
NO20035325D0 (no) 2003-11-28
MXPA03010991A (es) 2004-02-27
EA200301200A1 (ru) 2004-06-24
HUP0600294A2 (en) 2007-02-28
AP2003002922A0 (en) 2003-12-31
PL367337A1 (en) 2005-02-21
CR7173A (es) 2004-04-22
BR0210104A (pt) 2004-06-08
CZ20033241A3 (cs) 2004-08-18
MA27030A1 (fr) 2004-12-20
CO5640125A2 (es) 2006-05-31
OA12613A (en) 2006-06-09
SK14762003A3 (sk) 2004-08-03
KR20040033286A (ko) 2004-04-21
WO2002096435A3 (fr) 2003-05-01
CA2448627A1 (fr) 2002-12-05
WO2002096435A2 (fr) 2002-12-05
CN1547474A (zh) 2004-11-17
IL159100A0 (en) 2004-05-12
ECSP034869A (es) 2004-07-23
JP2004532871A (ja) 2004-10-28
EP1404345A2 (fr) 2004-04-07
ZA200309298B (en) 2004-05-12

Similar Documents

Publication Publication Date Title
TNSN03127A1 (fr) Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique
US7306812B2 (en) Dissolvable backing layer for use with a transmucosal delivery device
TNSN98059A1 (fr) Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant.
KR910009243A (ko) 치근막 질환 치료용 서방성 조성물
ATE229817T1 (de) Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
Shantiaee et al. Efficacy comparison of periapical infiltration injection of dexamethasone, morphine and placebo for postoperative endodontic pain
FR11C0006I1 (fr) Administration amelioree de medicaments sur des muqueuses
WO2002041883A3 (fr) Administration, au besoin, d'antidepresseurs tricycliques et d'autres antidepresseurs non inhibiteurs specifiques du recaptage de la serotonine (sri) pour traiter l'ejaculation precoce
JP2006528975A (ja) 経粘膜送達デバイスとともに使用のための溶解可能な裏打ち層
FR2569112A1 (fr) Systeme distributeur de medicaments par voie transcutanee
DE69814122D1 (de) Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
DK0969813T3 (da) Topisk farmaceutisk sammensætning omfattende et kolinergt middel eller et calciumkanalblokerende middel
DE602004026701D1 (de) Implantierbares medizinprodukt zur selektiven modulation der abgabe von mitteln in situ
DE69833000D1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
BRPI0410542A (pt) dispositivo de administração de medicamento para um olho e método de administrar um agente farmaceuticamente ativo a um olho
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
CA2383509A1 (fr) Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
ATE267583T1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
JPH059412B2 (fr)
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
DE69724599D1 (de) Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung
DE69730988D1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
Johnston Anatomy and physiology of the oral mucosa
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
Harari et al. Multifocal contact dermatitis to nitroderm TTS 5 with extensive postinflammatory hypermelanosis